Recombinant Equine Interleukin-1 Receptor Antagonist Protein ( Equine IL-1RA)_C230277

Description

Secreted equine IL-1 receptor antagonist (IL-1ra) is a presumably 22-25 kDa glycoprotein produced by variety of cell types that antagonizes IL-1 activity. It is a member of the IL-1 family of proteins that includes IL-1 alpha and IL-1 beta. Although there is little amino acid (aa) identity (< 30%) among the three IL-1 family members, all molecules bind to the same receptors, all show a beta -trefoil structure, and all are believed to have evolved from a common ancestral gene. Equine IL-1ra is synthesized as a 177 aa precursor that contains a 25 aa signal sequence plus a 152 aa mature region. There is one intrachain disulfide bond and one potential N-linked glycosylation site. Mature equine sIL-1ra is 78%, 78%, 80%, 82%, and 76% aa identical to mature mouse, human, porcine, canine and bovine IL-1ra, respectively. In human, three non-secreted IL-1ra isoforms have also been identified. It is unknown if such an analogous situation exists in equine. Cells known to secrete IL-1ra include fibroblasts, vascular smooth muscle cells, intestinal columnar epithelium, chondrocytes, macrophages, mast cells, neutrophils and hepatocytes. There are two type I transmembrane glycoprotein receptors for IL-1ra. The first is the bioactive 80 kDa type I IL-1 receptor (IL-1 RI), and the second is the inert (decoy) 65 kDa type II IL-1 receptor. IL-1ra binding to IL-1 RI competitively blocks IL-1 ( alpha or beta ) binding to the same receptor. This results in receptor ligation without activation. The type II IL-1 receptor is inert, and any binding of IL-1ra not only fails to block co-existing IL-1 activity, but may actually potentiate it by removing an IL-1 antagonist. Functionally, all activities attributed to IL-1ra are explained by its role as a competitive inhibitor of IL-1 binding to IL-1 RI.

Product Properties

Synonyms

IL-1RN, IRAP
Accession
O1899
GeneID
100034236
Source
E.coli-derived Equine IL-1RA, His26-Gln177.
Molecular Weight

Approximately 17.4 kDa.
AA Sequence
HPLGKRPCKM QAFRIWDVNQ KTFYMRNNQL VAGYLQESNT KLQEKIDVVP IEPDALFLGL HGRKLCLACV KSGDEIRFQL EAVNITDLSK NKEENKRFTF IRSNSGPTTS FESAACPGWF LCTAQEADRP VSLTNKPKES FMVTKFYLQE DQ
Tag
None
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Purity
> 95% by SDS-PAGE and HPLC analyses.
Biological Activity
The ED50 as determined by inhibiting IL-1α-dependent proliferation of murine D10S cells is less than 3.0 μg/mL, corresponding to a specific activity of > 333 IU/mg in the presence of 50 pg/mL rHuIL-1α. Fully biologically active when compared to standard.
Endotoxin
Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.
Formulation
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of
0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.


Shipping and Storage

The products are shipped with ice pack and can be stored at -20℃ to -80℃ for 1 year.
Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.

Cautions

1. Avoid repeated freeze-thaw cycles.
2. For your safety and health, please wear lab coats and disposable gloves for operation.
3. For research use only!

Recombinant Equine Interleukin-1 Receptor Antagonist Protein ( Equine IL-1RA)_C230277

Product form

SKU: C230277E

$82.00

    • Shipped today? Order within: Feb 17, 2025 17:00:00 -0500
    • Tell a unique detail about this product

    Description

    Secreted equine IL-1 receptor antagonist (IL-1ra) is a presumably 22-25 kDa glycoprotein produced by variety of cell types that antagonizes IL-1 activity. It is a member of the IL-1 family of proteins that includes IL-1 alpha and IL-1 beta. Although there is little amino acid (aa) identity (< 30%) among the three IL-1 family members, all molecules bind to the same receptors, all show a beta -trefoil structure, and all are believed to have evolved from a common ancestral gene. Equine IL-1ra is synthesized as a 177 aa precursor that contains a 25 aa signal sequence plus a 152 aa mature region. There is one intrachain disulfide bond and one potential N-linked glycosylation site. Mature equine sIL-1ra is 78%, 78%, 80%, 82%, and 76% aa identical to mature mouse, human, porcine, canine and bovine IL-1ra, respectively. In human, three non-secreted IL-1ra isoforms have also been identified. It is unknown if such an analogous situation exists in equine. Cells known to secrete IL-1ra include fibroblasts, vascular smooth muscle cells, intestinal columnar epithelium, chondrocytes, macrophages, mast cells, neutrophils and hepatocytes. There are two type I transmembrane glycoprotein receptors for IL-1ra. The first is the bioactive 80 kDa type I IL-1 receptor (IL-1 RI), and the second is the inert (decoy) 65 kDa type II IL-1 receptor. IL-1ra binding to IL-1 RI competitively blocks IL-1 ( alpha or beta ) binding to the same receptor. This results in receptor ligation without activation. The type II IL-1 receptor is inert, and any binding of IL-1ra not only fails to block co-existing IL-1 activity, but may actually potentiate it by removing an IL-1 antagonist. Functionally, all activities attributed to IL-1ra are explained by its role as a competitive inhibitor of IL-1 binding to IL-1 RI.

    Product Properties

    Synonyms

    IL-1RN, IRAP
    Accession
    O1899
    GeneID
    100034236
    Source
    E.coli-derived Equine IL-1RA, His26-Gln177.
    Molecular Weight

    Approximately 17.4 kDa.
    AA Sequence
    HPLGKRPCKM QAFRIWDVNQ KTFYMRNNQL VAGYLQESNT KLQEKIDVVP IEPDALFLGL HGRKLCLACV KSGDEIRFQL EAVNITDLSK NKEENKRFTF IRSNSGPTTS FESAACPGWF LCTAQEADRP VSLTNKPKES FMVTKFYLQE DQ
    Tag
    None
    Physical Appearance
    Sterile Filtered White lyophilized (freeze-dried) powder.
    Purity
    > 95% by SDS-PAGE and HPLC analyses.
    Biological Activity
    The ED50 as determined by inhibiting IL-1α-dependent proliferation of murine D10S cells is less than 3.0 μg/mL, corresponding to a specific activity of > 333 IU/mg in the presence of 50 pg/mL rHuIL-1α. Fully biologically active when compared to standard.
    Endotoxin
    Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.
    Formulation
    We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of
    0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.


    Shipping and Storage

    The products are shipped with ice pack and can be stored at -20℃ to -80℃ for 1 year.
    Recommend to aliquot the protein into smaller quantities when first used and avoid repeated freeze-thaw cycles.

    Cautions

    1. Avoid repeated freeze-thaw cycles.
    2. For your safety and health, please wear lab coats and disposable gloves for operation.
    3. For research use only!

    © 2025 Arcegen, Powered by Shopify

    • American Express
    • Apple Pay
    • Diners Club
    • Discover
    • Google Pay
    • Mastercard
    • Shop Pay
    • Visa

    Login

    Forgot your password?

    Don't have an account yet?
    Create account